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Abstract 
High-dose ivermectin, co-administered for 3-days with dihydroartemisinin-piperaquine (DP), killed 
mosquitoes feeding on individuals for at least 28-days post-treatment in a recent trial (IVERMAL), 
while 7-days was predicted pre-trial. The current study assessed the relationship between ivermectin 
blood concentrations and the observed mosquitocidal effects against Anopheles gambiae. 3-days 
ivermectin 0, 300, or 600 mcg/kg/day plus DP was randomly assigned to 141 adults with 
uncomplicated malaria in Kenya. During 28-days follow-up, 1,393 venous and 335 paired capillary 
plasma samples, 850 mosquito-cluster mortality rates, and 524 QTcF-intervals were collected. Using 
pharmacokinetic-pharmacodynamic (PK-PD) modeling, we show a consistent correlation between 
predicted ivermectin concentrations and observed mosquitocidal-effects throughout the 28-day study 
duration, without invoking an unidentified mosquitocidal metabolite or drug-drug-interaction. 
Ivermectin had no effect on piperaquine’s pharmacokinetics or QTcF-prolongation. The PK-PD model 
can be used to design new treatment regimens with predicted mosquitocidal effect. This methodology 
could be used to evaluate effectiveness of other endectocides. 
 
Introduction 
Mass drug administration (MDA) with the long-acting antimalarial dihydroartemisinin-piperaquine 
(DP) is being evaluated in several malaria endemic countries for malaria transmission reduction and 
elimination.1-3 Ivermectin is an antiparasitic drug, which also kills mosquitoes feeding on recently 
treated individuals. Adding ivermectin to DP has been proposed as an innovative tool to increase the 
impact of MDA for malaria.4 However, the single dose of 150-200 mcg/kg ivermectin used for 
onchocerciasis and lymphatic filariasis control has only a small and short-lived effect (<7 days) on 
mosquito mortality.5 Ivermectin is documented to be remarkably well tolerated, even up to doses of 
2,000 mcg/kg.6, 7  
 
In a recent randomized, double-blind, placebo-controlled trial in western Kenya, ivermectin 300 and 
600 mcg/kg/day, co-administered for 3 days with DP, were shown to kill mosquitoes feeding on 
individuals for at least 28-days post-treatment.8 This was significantly longer than the 7-day 
effectiveness expected based on the predicted time ivermectin would remain above the in vitro 
median lethal concentration (LC50) for Anopheles gambiae in pre-trial simulations.5 Two possible 
explanations are an unidentified mosquitocidal metabolite with a longer active half-life than the 
parent compound ivermectin or a drug-drug interaction that results in a slower clearance of 
ivermectin from the circulation. As ivermectin and piperaquine are both metabolized by cytochrome 
P450 3A4 (CYP3A4), it has been hypothesized that an interaction could occur.5 Using the trial data, the 
current pharmacokinetic and pharmacodynamic analysis aimed to determine whether a drug 
interaction or an unidentified ivermectin metabolite could be contributing to the prolonged 
mosquitocidal effect of ivermectin.  
 
Results 
Ivermectin PK 
Ivermectin pharmacokinetics were best described by a two-compartment oral absorption model 
(Figure S1, Table S1). The initial sequential model, utilizing only plasma concentration data to fit the 
PK data, resulted in the parameters described in Table 1. Goodness-of-fit plots are shown in Figure 1 
(observed capillary-venous plots are shown in Figure S2). In the ivermectin arms post-treatment, 
concentrations were below the limit of quantification (BLQ) for 277 of 805 (34.4%) venous and 44 of 
224 (19.6%) capillary samples, predominantly at later time points (Table S2).  
 
The subsequent simultaneous PK-PD model resulted in remarkably similar PK parameters to the initial 
sequential approach (Table 1), meaning the PD element did not disturb the PK prediction, which 
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supports the notion that it is unnecessary to invoke an active metabolite to explain the 
pharmacodynamic output of ivermectin. 
 
Piperaquine PK 
Piperaquine pharmacokinetics were best described using a three-compartment oral absorption model 
(Figure S1, Table S1), resulting in the parameters displayed in Table 1. Concentrations were below the 
limit of quantification (BLQ) for 3 of 1248 (0.2%) venous and 0 of 333 (0%) capillary post-treatment 
samples (Table S2). Goodness-of-fit graphs including both capillary and venous concentrations are 
shown in Figure 2 (observed capillary-venous plots are shown in Figure S2). A visual predictive check, 
incorporating variation in patient weights, resulted in a profile which accurately fits the observed 
population pharmacokinetic data (Figure 2, e). Post-hoc analysis showed that piperaquine PK was not 
influenced by ivermectin with AUC, Cmax, terminal t1/2 (Table 1) and the overall PK profile (Figure 2, f) 
showing no differences across all three study arms. 
 
Ivermectin PD 
Pharmacodynamic analysis of ivermectin activity was performed initially by building an exposure-
effect relationship between pooled observed venous ivermectin concentrations in patients and the 
corresponding mosquitocidal activity of each blood sample (Figure 3, a). This generated ivermectin’s 
predicted half-maximal effective concentration (EC50) of 11.3 ng/mL and maximal mosquito mortality 
rate (Emax+ Emin) of 48.8 deaths per 100 mosquito days observed (an incidence density rate). Baseline 
mortality rate (Emin) was fixed to 3.7 deaths/100 days based on mortality rates observed in 392 
mosquito clusters feeding on ivermectin-free blood from baseline and control samples.  
 
The relationship between mosquitocidal activity and pooled predicted ivermectin concentrations from 
the sequential PK-PD model (including 321 BLQ venous and capillary concentrations that were 
predicted but not observed) resulted in a similar predicted pharmacodynamic response, compared to 
analyzing observed data only (Table 2 and Figure 3, b). A sequential population method, incorporating 
individual PK parameters (assessed previously) and individuals’ corresponding PD output, gave similar 
results: predicted median maximal mosquito mortality rate (Emax+ Emin) of 57.3 [p5-p95: 42.1-68.8] 
deaths per 100 mosquito days, median EC50 of 20.5 ng/mL [p5-p95: 6.1-49.7], and median Emin of 3.84 
[p5-p95: 3.6-4.4] deaths per 100 mosquito days. Finally, the simultaneous PK-PD model resulted in 
pharmacodynamic parameters that are very similar to those obtained from utilizing the sequential 
models or observed data only (Table 2 and Figure 3, c). 
 
The relationship between ivermectin exposure and its mosquitocidal effect was investigated 
separately for each day of follow-up (days: 2+4h, 7, 10, 14, 21 and 28). As most samples beyond day 
14 resulted in unquantifiable concentrations (BLQ), which would have restricted the ability of PD 
analysis, predicted concentrations from the sequential PK model (using PK data from all days) were 
used for PD modeling; this was justified as predicted concentrations matched observed values 
accurately (Figure 1, A & Figure 3, B). Figure 4 shows the relationship between predicted ivermectin 
exposure and mosquito mortality rate at each study visit. The results indicate that the mosquito 
mortality rate has the same relationship with predicted ivermectin concentration at all post-treatment 
feeding days of the study, including days 21 and 28 when most ivermectin exposures were BLQ. There 
is no effect of time post-treatment on the shape of the sigmoidal relationship between predicted 
ivermectin concentration and observed mortality rate. Similar to this sequential PK-PD approach, the 
simultaneous PK-PD model showed no bias over time in residual analysis of PD predictions, meaning 
ivermectin’s concentration-effect relationship (i.e. EC50 and Emax) was consistent through-out the 
study duration (Figure S4). 
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Mosquito mortality was also analyzed as a proportion (%) to calculate the ivermectin concentration 
able to kill 50% of mosquitoes by a specific time point (LC50), unadjusted and adjusted for baseline 
mortality (Figure S3, Table S3). 
 
Ivermectin PK-PD simulation 
A visual predictive check of the PK-PD simulation did not show any bias in comparison with observed 
PD data in either arm of the study (Figure 5). 
 
Piperaquine PD 
Piperaquine’s effect upon QTcF was analyzed using a conventional linear model as well as a dynamic 
Emax model. Using the linear model, piperaquine resulted in a mean QTcF-prolongation of 3.71 ms 
(95% CI: 3.12-4.29) per 100 ng/mL with a baseline intercept of 6.76 ms (95% CI: 4.99-8.53) (Figure S5). 
Using the dynamic Emax population model, that was simultaneously fitted with piperaquine PK using 
Pmetrics™, we show that from a median baseline QTcF-interval of 399.3 ms [p5-p95: 377.5-416.3] the 
maximal ΔQTcF-interval was estimated at 53.5 ms [31.1-122.9], resulting in a maximal QTcF-interval 
of 449.8 ms [415.1-520.0]. The median concentration required to achieve an effect half-way between 
baseline and maximal possible prolongation (EC50) was 181.7 ng/mL [16.0-1200.0]. Parasitemia, 
present at low levels and only at baseline, was not associated with QTcF at baseline versus day 28, at 
day 2+4h versus day 0, or at day 2+4h versus day 28. 
 
Piperaquine concentration correlated with QTcF (Figure S5), however post-hoc analysis showed only 
a weak (ρ<0.3), albeit significant, correlation between piperaquine Cmax and D2+4h QTcF (Table S6). 
Piperaquine AUC was not correlated with D2+4h QTcF and ΔQTcF (Table S6). Ivermectin dose did not 
modify piperaquine’s QTcF-prolonging effect (Table S4 and Table S5). 
 
Discussion 
Ivermectin’s pharmacodynamic effect on An. gambiae mortality was much stronger and persisted 
much longer post-treatment in the current trial than reported in previous studies. Pharmacokinetic-
pharmacodynamic analysis showed that the entire 28 days of mosquitocidal effect post-treatment 
observed in the main trial8 could be explained by ivermectin concentrations alone, without invoking 
unidentified variables such as an active metabolite or a drug-drug interaction. Furthermore, 
ivermectin exerted no modification of piperaquine’s pharmacokinetics or QTcF-prolongation. This 
ivermectin PK-PD model can be used to design new treatment regimens and predict their 
mosquitocidal effect. The methodology could also be used to assess new endectocides. 
 
Ivermectin PK 
Ivermectin pharmacokinetic properties in this study were similar to those reported in earlier studies, 
which used venous concentrations from adults receiving single doses ranging between 150 and 2,000 
mcg/kg,7, 9-14 and repeated doses up to 1,000 mcg/kg given three-times in 1 week.7 Ivermectin 
clearance has been reported as 19.2 L/h (SD ±14.8),10 17.3 L/h (SD ±9.2),14 and in a study with co-
administration of azithromycin and albendazole, as 11.8 L/h (RSE 32.8%) overall, and 12.3 L/h (RSE 
42.6%) when allowing for different sub-populations.11 Clearance in the current study using a 
simultaneous model was 10.9 L/h for an average 60 kg patient (Table 1), which is similar to previous 
studies and makes a drug-drug-interaction in the current study unlikely. 
 
Ivermectin PD 
Ivermectin’s mosquitocidal effect has been assessed in several in vitro studies with spiked blood and 
three previous clinical trials, one of which measured plasma concentrations. Outcomes are often 
expressed as the LC50 by a specified time post-feeding (e.g. by 7 days), although assay durations vary 
widely, as does adjustment for background mortality rate, hampering comparability. In vivo adjusted 
LC50 values in the current trial were 0.6, 2.6, 4.3, 4.7, and 7.1 times lower than previous studies (Figure 
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S3, Table S3).15-18 Noticeably there was no major difference between the current study and the 
previous in vivo trial (adjusted LC50: 2.6 vs 6.5 ng/mL), especially considering the later value could be 
an overestimation due to a scarcity of data in the upper ranges of concentrations (maximum value 
achieved: 15.6 ng/mL) and mosquito mortality rates (2 of 233 values were >90%).15 Any major 
difference between LC50 estimates obtained from in vivo and in vitro studies could suggest the 
presence of an active metabolite, however, comparisons between the current in vivo trial and the in 
vitro studies were inconclusive, some showing either lower (0.6 fold) or higher (7.1 fold) values. 
Nevertheless, our PK-PD model showed that the entire mosquitocidal effect, including its prolonged 
effect beyond day 7 up to day 28 post-treatment, could be explained by ivermectin concentrations 
alone, without the need to invoke an unidentified metabolite (Figure 5, Table 2, Figure S4). This 
indicates that ivermectin in its parent form is likely the sole contributor to the observed mosquitocidal 
effect for the duration of the study, or if an active metabolite is present, then it must have a 
remarkably similar pharmacokinetic profile to ivermectin itself.  
 
Ivermectin effect-duration 
The 28-day exposure-effect relationship exceeded the prediction from the pre-trial pharmacodynamic 
simulation which estimated an effect-duration of only 7 days.5 The simulation was based on previously 
reported 7-day-LC50 value of ivermectin of 15.9 ng/mL,17 while in the current trial the 7-day-LC50 was 
3.4 ng/mL. Importantly, this study also illustrated the value of using thresholds below the LC50 to help 
explain the effect-duration, such as 5% and 1% of maximal activity (EC5 0.83 ng/mL and EC1 0.16 
ng/mL), which were reached at 20.1 and 28.1 days post-treatment with the 3-day 600 mcg/kg/day 
regimen (Table 2). The latter is consistent with the observed 28-day mosquitocidal effects of the main 
trial.8 Future pharmacodynamic simulations should consider using these EC1-EC5 concentrations as 
thresholds to predict effect-durations.  
 
With this PK-PD model we also show that the high-dose regimens can extend the time that 5% of 
maximal activity against mosquitoes is achieved from 13 days with a single-dose of 400 mcg/kg to 23 
days with the 3-day 600 mcg/kg/day regimen; additionally the overall kill rate using the 3-day 600 or 
300 mcg/kg/day regimens is predicted to be several fold faster in the first two weeks of treatment 
when compared to the 400 mcg/kg single-dose (Figure 5).  
 
Assessing endectocides 
Other aspects of the methodology followed in this analysis may also be useful for further assessment 
and comparisons of new endectocides and regimen optimization.19 We propose to collect the 
following data for each drug: Emax, Emin, EC50, Hill coefficient (in this study equaling 1), and PK 
parameters (e.g. CL, V, Q1/F, VP1/F and ka) to allow for PK-PD simulation. E is specific to the mosquito 
species studied. We also propose to express the pharmacodynamic effect of each endectocide on 
mosquito mortality as an incidence density rate (IDR) by day 14 (i.e. deaths per 100 mosquito days 
observed, during a 14-day mosquito survival assay). The 14-day follow-up is required to capture the 
cumulative effect during a prolonged extrinsic cycle. The use of IDR’s instead of hazards are 
recommended, as rates, are easier to interpret and incorporate in PK-PD models. For example, in the 
PK-PD simulation it was possible to simulate an IDR for any desired drug regimen at any time post-
treatment. By dividing the drug IDR (E) by the baseline mortality rate (Emin) it was then possible to 
calculate the incidence rate ratio (IRR = E / Emin) at each timepoint (see IVERMAL Dose-Response 
Calculator and Figure 5d). Both IRR’s and HR’s assess the relative differences in incidence rates, can 
be interpreted in roughly the same way,20 and equally incorporated into population models. As MDA 
rounds are likely to be spaced at least 1 month apart, determining an endectocide’s IRR at 28 days 
post-treatment (either directly or by simulation) may be a useful measure to assess prolonged 
effectiveness. 
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Ivermectin capillary concentrations 
No previous studies assessed capillary concentrations of ivermectin; the current study identified a 
capillary-venous ratio of 1.33 [0.98-1.63] ±29.1%, which was consistent over time from day 2-7 post-
treatment (Table 1, Figure S2). In the current assays, mosquitoes were fed venous blood via artificial 
membranes. As capillary concentrations of ivermectin were found to be higher (Table 1), and that 
when mosquitoes bite humans directly they are more likely to feed from capillary blood, the 
mosquitocidal effects of ivermectin might be higher than presented in the current study. To assess 
this, an analysis is ongoing comparing mosquito mortality following direct skin feeding (from capillary 
blood) versus membrane feeding (from venous blood). 
 
Piperaquine PK 
Piperaquine pharmacokinetics have been described using meta-analysis, across age-groups, and using 
capillary sampling, with clearance reported as 55.4 L/h (RSE 4.2%; for an average 54 kg patient),21 
which was somewhat higher in the current study at 97.1 L/h (IIV ±49.1%; for an average 60 kg patient). 
The majority of previous studies were performed in Asian patients while this study was performed in 
Kenyan patients. Whilst the current clearance value had a relatively wide percentile range [p5-p95: 
20.0-177.3], more studies in African patients might be needed to investigate whether genetics plays a 
role in piperaquine clearance. The plasma capillary-venous ratio of 1.55 ±36.1% was similar to those 
reported previously for blood (1.66)22 and plasma (1.9,23 1.63,24 and 1.41 25). Using a linear model, 
piperaquine’s pharmacodynamic effect on QT-interval was also similar to previous studies,26-29 with 
the current trial predicting a ΔQTcF-prolongation of 3.71 ms (95% CI: 3.12-4.29) per 100 ng/mL of 
piperaquine. Additionally, using a dynamic Emax model, that simultaneously incorporated piperaquine 
PK and PD data, we estimated maximal QTcF (449.8 ms) and maximal ΔQTcF (53.5 ms) using 
population methods (Table S5 and Figure S5). Importantly, neither of the two ivermectin regimens 
used in the study altered piperaquine’s pharmacokinetics or dynamics (Table 1, Figure 2f, Table S4, 
and Table S5).  
 
Drug interaction 
It is not possible to completely rule out an effect of DP on ivermectin’s pharmacokinetics or 
pharmacodynamics, as all groups received DP. Nonetheless a substantial drug-drug interaction is 
unlikely as ivermectin PK parameters were very similar to previously reported values (Table 1) and 
within our prediction, which was based on published data where ivermectin was given alone.5 Future 
studies comparing ivermectin alone versus ivermectin with DP could help to further assess any 
potential effect of DP on ivermectin PK-PD. 
 
Limitations and future studies 
A limitation of this PK-PD analysis was that the LLQ for ivermectin was relatively high (venous: 5 ng/mL, 
capillary: 10 ng/mL), resulting in undetectable concentrations for 34% of venous and 20% of capillary 
samples in the ivermectin arms post-treatment, predominantly at later timepoints. Previous studies 
used venous LLQ’s of: 0.2,30 1.0,31 0.5,7 2.5,11 0.2,15 0.8,32 ng/mL. Based on the number of samples 
available it was still possible to generate an accurate PK-PD model, however future studies should 
attempt to use assays with lower LLQ’s to make full use of the available samples and detect ivermectin 
at the very low concentrations that it still has a mosquitocidal effect. Another possible limitation is 
that this study used a homogeneous laboratory-reared mosquito colony which may not be reflective 
of wild populations. Although previous work has demonstrated that ivermectin affects survival of all 
tested anophelines (≥17 species tested),33 future studies would be beneficial to examine possible 
(heterogeneity of) effects of ivermectin against wild populations.8 Finally, this study included only 
(non-pregnant) adults, whereas the targeted population for MDA also includes children and pregnant 
women. Children are hypothesized to have faster ivermectin metabolism based on increased CYP3A4 
expression.34 Ivermectin is currently contra-indicated in pregnancy, however inadvertent exposures 
during MDA for lymphatic filariasis and onchocerciasis have not led to an increase in adverse events.35 
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Further studies assessing the safety, efficacy, and pharmacokinetics of (high-dose) ivermectin are 
needed in children and pregnant women. 
 
Prolonging mosquitocidal effects 
Additional effort is also required to further increase ivermectin’s effect-duration past 28 days, as a 
longer effect-duration would allow MDA rounds to be more widely spaced and reduced in number. 
Consideration could be given to developing slow-release tablet formulations, to developing gastric-
resident devices,36 or to other similar drugs with a long half-life, such as moxidectin, albeit its LC50 of 
2,789 ng/mL against An.gambiae does not seem to make it very suited for malaria control.12, 37 
 
Conclusion 
In conclusion, the current pharmacokinetic-pharmacodynamic model predicted that the 
mosquitocidal effect of high-dose ivermectin lasted for at least 28 days post-treatment, consistent 
with the in-vivo observations from the main trial.8 This effect could be explained by ivermectin 
concentrations alone, without invoking unidentified variables such as an active metabolite or a drug-
drug interaction. Furthermore, ivermectin exerted no modification of piperaquine’s pharmacokinetics 
or QTcF-prolongation. The presented ivermectin PK-PD model can be used to design new treatment 
regimens and predict their mosquitocidal effect. The presented methodology may be useful for the 
assessment of new endectocides. 
 
Methods 
Trial design 
Details of the trial design, procedures and main results were published elsewhere.5, 8 Briefly, the study 
was a randomized, double-blind, placebo-controlled, parallel 3-arm, superiority trial 
(ClinicalTrials.gov: NCT02511353). 141 adults with uncomplicated malaria in western Kenya were 
randomly assigned (1:1:1), stratified by sex and body-mass index, to receive 3 days of ivermectin 600 
mcg/kg/day (n=47), 300 mcg/kg/day (n=48), or placebo (n=46), all co-administered with 3 days of DP. 
The primary outcome was the effect of ivermectin-dose on mosquito mortality. For safety, the effect 
of ivermectin-dose on piperaquine concentration and piperaquine-induced QTcF-prolongation were 
also assessed. Venous plasma was collected from day 0 to day 28 using both rich and population 
sampling strategies. Additional capillary plasma was collected using finger-pricks from day 2+4h (4 
hours after the third dose) to day 7, concomitantly with the venous population sampling. Capillary 
sampling might be useful for subsequent pediatric or field trials and might be more representative of 
the blood that mosquitoes feed on.  
 
Observed plasma concentrations and outcome data 
During 28 days of follow-up, 1,393 venous and 335 paired capillary plasma samples, 850 mosquito-
cluster mortality rates (from 91,109 mosquitoes), and 524 QTcF-intervals were collected (Table S2). 
Drug analytical quantification was performed by LC-MS/MS (Text S1); only quantifiability and not 
detectability was considered. Ivermectin venous concentrations were above the lower limit of 
quantification (LLQ: 5 ng/mL) for 534 samples, of which 246 had paired mortality rates, and capillary 
concentrations were above LLQ (10 ng/mL) for 181 samples. Piperaquine venous concentrations were 
above the LLQ (1.5 ng/mL) for 1,246 samples, of which 251 had paired QTcF-intervals, and capillary 
concentrations were above LLQ (1.5 ng/mL) for 333 samples. 
 
Pharmacokinetic and pharmacodynamic analysis 
Pooled exposure-effect analyses were performed using Prism© v7.00. Population pharmacokinetic 
and pharmacodynamic (PK-PD) modelling and fitting of data were independently performed for 
ivermectin and piperaquine concentrations using Pmetrics™ v1.5.0.38 All PK and PK-PD modelling done 
with Pmetrics™ utilized the non-parametric adaptive grid (NPAG) for finding the non-parametric 
maximum likelihood estimate of the population distribution. Samples which were below the limit of 
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quantification were indicated in the Pmetrics data file as “-99” and the lower limit of quantification 
was incorporated into the overall standard population error model. A proportional scaling factor was 
used to fit venous and capillary concentrations simultaneously for each drug model (Supplementary 
Equations). 
 
Residual analysis was performed for all predicted PK and PD data in Pmetrics. This included goodness-
of-fit comparisons of individual and population predictions against observed data, as well as weighted 
residuals over time and concentration, to investigate any biases towards higher concentrations or 
later time points. Visual Predictive Checks (VPCs) were performed using the Pmetrics™ simulator tool, 
where 1,000 subjects were simulated based on the generated median PK parameters, their variances 
and correlation matrices as generated in Pmetrics™ for each drug. Additionally, weight variation 
among patients and associated dosing brackets were included in the simulation. The weight variation 
was set to match that of the study population and a median of 60 kg patient weight were used for the 
simulation. The Pmetrics simulator predicted patients’ weights for 1,000 patients in the range of 45-
101 kg, which is the range of this study. The median, 5% and 95% percentiles with their 95% confidence 
intervals were plotted against observed data for the VPC graphs. A similar simulation was done using 
a simultaneous PK-PD model with 1,000 subjects to predict the overall mosquitocidal activity in the 
study population. To avoid the complexity of adding different dosing brackets to different patient 
weights, simulations were performed with a standard patient weight only, which is 600 mcg/kg/day 
or 300 mcg/kg/day administered to 60 kg patients. The wide margins used for CL/F and V/F would 
account for more variability than that introduced by variability in weight.  
 
Ivermectin PK-PD analysis 
Modelling ivermectin was performed using multiple approaches to address several questions about 
its PK-PD relationship against mosquitoes. As it had been hypothesized that ivermectin’s 
mosquitocidal effects at later timepoints could be due a metabolite or drug-drug-interaction, an 
initial sequential analysis (using three approaches, see below) was performed to justify a final 
simultaneous analysis. The sequential analysis, where the PK model is blinded to PD data, assessed 
the consistency of ivermectin’s exposure-effect relationship over time. The simultaneous analysis 
presumes ivermectin concentrations alone can explain the mosquitocidal activity; this allows for the 
model to predict best PK and PD parameter estimates using both pharmacokinetic and 
pharmacodynamic data simultaneously to achieve well-informed parameters that are derived from 
two sets of data (pharmacokinetic and pharmacodynamic data) rather than parameters being 
informed by a single set of data (i.e. pharmacokinetic information only, as in the first step of the 
sequential model).   
 
Sequential modelling approach 
For both the sequential and simultaneous approaches, pharmacokinetic analysis was performed 
using a two-compartment model (Figure S1), which displayed a better fit than a one compartment 
model (Table S1). A three-compartment model fit was not attempted for ivermectin as predictive 
visual checks showed that ivermectin follows a two-compartment model trend and does not display 
a tri-exponential trend. The two-compartment PK model was performed using Equations S1-S13 
(Supp. Materials).  
 
Pharmacodynamic analysis of the relationship between ivermectin concentrations and mosquitocidal 
effect was performed according to the following Emax sigmoidal equation: 
 
𝐸𝐸 =  𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚∙𝐶𝐶
𝐸𝐸𝐶𝐶50+𝐶𝐶
+ 𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚                …………. (Eq. 1)39 
 
Where E represents the mosquitocidal effect of ivermectin expressed as the mortality rate of 
mosquitoes per 100 days, Emin is the baseline natural mortality rate, Emax is the maximal possible effect 
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relative to Emin, EC50 the concentration necessary to achieve a rate halfway between baseline and 
maximal effect (Emax+Emin), and C is ivermectin concentration in grams/liter. 
 
The sequential PD analysis was performed using three approaches. The first was fitting an Emax 
function through observed mosquito mortality rates and pooled observed concentrations in Prism 7®. 
The second followed the same methodology using predicted concentrations in order to assess 
whether (BLQ) concentrations predicted by the Pmetrics™ PK model (blinded to PD data) showed a 
similar exposure-effect relationship to observed concentrations. The third approach used Pmetrics™ 
for the population modelling of both PK and PD separately, where each patient in the PD analysis had 
fixed PK parameters which matched their individual predicted parameters in the PK run. This allowed 
predicting population variability on PD parameters using the sequential PK-PD model (which cannot 
be assessed using pooled data in the previous two approaches). 
 
The relationship between ivermectin exposure and its mosquitocidal effect was investigated 
separately for each day of the study (days: 2+4h, 7, 10, 14, 21 and 28), using predicted PK 
parameters (second sequential model), as any time-dependent variation could potentially suggest 
the presence of an unidentified mosquitocidal metabolite. 
 
Simultaneous modelling approach 
The simultaneous approach used the same equations above, however all available PD data (ivermectin 
mosquito mortality rates) were entered into the initial modelling process and both the PK and the PD 
data for all subjects were modelled simultaneously, allowing for PD data to enhance the PK fit, and 
vice versa, based on the assumption that ivermectin in its parent form is solely responsible for any 
increase in the mosquito mortality rate through-out the study duration. 
 
Piperaquine PK 
Piperaquine PK was analyzed using a three-compartment model (Figure S1) according to the 
Equations S1-S13 (Supp. Materials). This was compared to one and two compartment models which 
resulted in poorer fits as evidenced from -2 loglikelihood and AIC and BIC criteria (Table S1). 
 
Piperaquine PD 
Piperaquine effect upon QTcF-interval was analyzed using two methods: (1) a linear model, 
according to equation 2 below, which is commonly used in similar published analyses, and (2) an 
Emax sigmoidal model, utilizing previously discussed equation 1, with the effect (E) being QTcF-
interval in milliseconds at any given concentration, and C being piperaquine concentration. The data 
was either analyzed using pooled observed piperaquine concentration versus QTcF-interval (linear 
model) or simultaneously fitted using a population method with Pmetrics™ as described for the 
simultaneous ivermectin PK-PD model (Emax model). 
 
∆𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄 = 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑄𝑄𝑖𝑖𝑖𝑖𝑖𝑖 + 𝑠𝑠𝑠𝑠𝑠𝑠𝑖𝑖𝑖𝑖 ∙ 𝐶𝐶                                                     ………… (Eq. 2) 
 
The slope represents the relationship between piperaquine concentration in ng/mL and the change 
in QTcF (∆QTcF) in milliseconds. 
 
Secondary PK Parameters Post-hoc Statistical Analysis 
AUC0-28d is defined as the predicted area under the curve for 3 doses of ivermectin or piperaquine 
over a period of 28 days and was determined using the AUC trapezoidal approximation algorithm in 
Pmetrics™ for each subject individually. Cmax represents the maximal predicted concentration for each 
subject in the study. Tmax is the time at which Cmax is achieved for each individual and terminal t1/2 is 
calculated from the predicted PK slope for each individual between 27-29 days after treatment.  
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The primary PK parameters for ivermectin (ka, Q1/F, VP1/F, CL/F, V/F) and primary PK parameters 
for piperaquine (ka, Q1/F, VP1/F, Q2/F, VP2/F, CL/F, V/F) and secondary PK parameters for both drugs 
(Cmax, AUC0-28d) for each subject in the study were correlated to each other as well as with age, sex, 
weight, height, QTcF interval (measured at days 0, 2, 2+4h, and 28 after dosing initiation) or mosquito 
mortality rate (at each study time point). Correlation analysis was done using SPSS® v.24 (IBM Corp®) 
using Spearman bivariate correlation to identify any possible effects that require further analysis. This 
included any effect of ivermectin exposure upon piperaquine, exploring any possible interaction 
between study arm (i.e. ivermectin dose 0, 300, or 600 mcg/kg/day), interaction between all structural 
parameters (e.g. CL, V, Q1/F, VP1/F, and ka), and interaction between observed and predicted Cmax, 
and AUC for both drugs. Correlations were considered significant if ρ>0.3 and p<0.05. 
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Study Highlights: 
What is the current knowledge on the topic? 
Ivermectin has been shown, in-vitro and in-vivo, to kill malaria mosquitoes after feeding on human 
blood. Previous clinical studies showed an effect for 7 days post-treatment. A recent clinical trial 
showed a prolonged effect for at least 28 days post-treatment. 
What question did this study address? 
Using data from the recent trial, this study explored the PK-PD relationship between ivermectin 
(when co-administered with the antimalarial dihydroartemisinin-piperaquine) and the observed 
mosquitocidal effects, in order to understand whether an unidentified metabolite or an ivermectin-
piperaquine drug interaction could be contributing to the prolonged effect.  
What this study adds to our knowledge? 
The study shows a time-independent PK-PD relationship between ivermectin exposure in individuals 
and its mosquitocidal activity, without the need to invoke unidentified variables such as an active 
metabolite or a drug-drug interaction.  
How this might change clinical pharmacology or translational science 
A comprehensive PK-PD model able to predict the mosquitocidal effect of varying ivermectin regimens 
in this population can be utilized in guiding future studies and mass drug administration for malaria 
elimination programs.
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AUC Area under the curve 
BLQ Below Limit of Quantification 
BMI Body Mass Index 
CDC Centers for Disease Control and Prevention 
CI Confidence Interval 
Cmax Maximum drug concentration 
CYP Cytochrome P450 
E Effect of drug on outcome measure (e.g. mosquito mortality rate) 
Emin Minimum possible effect (e.g. the effect without exposure to the drug). 
Emax Maximal possible effect of the drug relative to Emin. 
Exx XX% of effect between Emin and Emax+Emin 
ECxx Concentration at which Exx is achieved. 
DHA  Dihydroartemisinin 
DP Dihydroartemisinin-piperaquine 
IRS Indoor Residual Spraying 
IVM Ivermectin 
IQR Inter Quartile Range 
JOOTRH Jaramogi Oginga Odinga Teaching and Referral Hospital 
KEMRI Kenya Medical Research Institute 
LC50, unadjusted Unadjusted Lethal Concentration 50%: within a specified assay duration, 
the drug concentration killing 50% of all mosquitoes (incl. those that 
would have died anyway). 
LC50, adjusted Adjusted Lethal Concentration 50%: within a specified assay duration, the 
drug concentration killing 50% of mosquitoes that normally would have 
survived (excl. those that would have died anyway). 
LC-MS/MS Liquid chromatography – tandem mass spectrometry 
LLIN’s Long-lasting Insecticide Treated Nets 
LLQ Lower Limit of Quantification 
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LSTM  Liverpool School of Tropical Medicine 
MDA Mass drug administration 
MESA Malaria Eradication Scientific Alliance 
MoH Ministry of Health 
PD Pharmacodynamic 
PK Pharmacokinetic 
PPQ Piperaquine 
QTc Electrocardiogram QT-interval, corrected for heart rate 
QTcF QTc, corrected for heart rate using Fredericia’s formula 
ΔQTc QTcF, adjusted for baseline 
ΔΔQTc QTcF, adjusted for baseline and placebo 
Txx Time post-treatment at which ECxx and Exx are achieved. 
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Figure Legends 
Figure 1 Ivermectin pharmacokinetic model (sequential approach) using venous and capillary 
concentrations: goodness-of-fit and simulation. (a) Ivermectin individual predicted concentrations 
(n=1029) versus observed concentrations (n=708) (slope=0.98, R2=0.8652). (b) Ivermectin population 
predicted concentrations versus observed concentrations (slope=0.81, R2=0.5793). (c) Weighted 
residual error distribution of predicted versus observed ivermectin concentrations over time (mean=-
0.23 over 28 days) (dashed black line= LOESS curve fit through residuals). (d) Weighted residual error 
distribution of predicted versus observed ivermectin concentrations over predicted ivermectin 
concentration (mean=-0.23 over a range of 1 to 353 ng/mL) (dashed black line= LOESS curve fit 
through residuals). (e) Observed ivermectin venous concentrations (grey circles) with predicted 
concentrations for those unobserved (gray squares), overlaid with simulation of ivermectin 300 
mcg/kg/day for 3 days (solid black line= median; dashed grey lines= 5% and 95% percentiles; shaded 
grey area= 95% CI for the percentiles). (f) Similar to (e) with ivermectin 600 mcg/kg/day for 3 days. 
IVM=ivermectin. Conc.=concentration. LLQ=lower limit of quantification, 5 ng/mL (horizontal grey 
line). Simulations included 1,000 individuals of 60 kg bodyweight. 
Figure 2 Piperaquine pharmacokinetic model using venous and capillary concentrations: goodness-of-
fit and simulation. (a) Piperaquine individual predicted concentrations (n=1581) versus observed 
concentrations (n=1578) (slope=1.04, R2=0.9273). (b) Piperaquine population predicted 
concentrations versus observed concentrations (slope=0.93, R2=0.8332). (c) Weighted residual error 
distribution of predicted versus observed piperaquine concentrations over time (mean=-0.23 over 28 
days) (dashed black line= LOESS curve fit through residuals). (d) Weighted residual error distribution 
of predicted versus observed piperaquine concentrations over predicted ivermectin concentration 
(mean=-0.20 over a range of 2 to 1421 ng/mL) (dashed black line= LOESS curve fit through residuals) 
(e) Observed piperaquine venous concentrations (grey circles) overlaid with simulation of piperaquine
960 mg/day for 3 days (solid black line= median; dashed grey lines= 5% and 95% percentiles; shaded
grey area= 95% CI for the percentiles). (f) Simulation of piperaquine 960 mg/day for 3 days based on
parameters derived from patients concomitantly receiving ivermectin 0 mcg/kg/day (solid black line),
ivermectin 300 mcg/kg/day (solid grey line) or ivermectin 600 mcg/kg/day (black dashed line).
PPQ=piperaquine. Conc.=concentration. LLQ=lower limit of quantification, 1.5 ng/mL (horizontal grey
line). Simulations included 1,000 individuals of 60 kg bodyweight.
Figure 3 (a) Relationship between observed ivermectin venous concentration and mosquito 
mortality rate (/100 days). Open circles (n=246 concentrations above LLQ with paired mortality rate) 
represent observed data. The solid line represents sigmoidal three-parameter Emax fit. (b) Similar to 
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(a), however now overlaid with predicted ivermectin venous concentrations for all samples 
(including those that were below LLQ) with observed mosquito mortality rates in patients that 
received ivermectin (grey squares, n=567). The dashed line represents the sigmoidal three-
parameter Emax fits for the predicted concentrations. (c) A comparison between the exposure 
relationship of (a), (b) and the exposure-effect relationship generated using the simultaneous PK-PD 
model which incorporated PD data in the process of PK modelling and vice versa. 
Figure 4 The exposure-effect relationship between predicted ivermectin concentrations (from the 
sequential PK model, using PK data from all days) and corresponding observed mosquito mortality 
rates separated by day of analysis after initiation of treatment. Emin and Emax were fixed to the 
values determined by analyzing the entire dataset and EC50 concentrations (95% CI’s) were 
estimated as shown in the figure. 
Figure 5 Ivermectin pharmacokinetic and pharmacodynamic simulation of mosquito mortality rate 
(using simultaneous approach) with (a) 300 mcg/kg/day for 3 days, and (b) 600 mcg/kg/day for 3 
days. Mosquito mortality rate simulated median (solid black line), 5th and 95th percentiles (dashed 
lines), and 95% confidence intervals (shaded grey areas), with observed mosquito mortality rates per 
sample (open circles), observed median±IQR mortality rate per study visit (ball-whiskers), and Emin 
(horizontal dashed line). (c) Comparison of both regimens with a simulation of the standard 150 
mcg/kg single-dose. Simulations included 1,000 individuals of 60 kg bodyweight. (d) Mortality rate 
ratios calculated as incidence rate ratios using the PK-PD model (IRR; lines) and as hazard ratios with 
95% confidence intervals as per main efficacy results8 (HR; triangles: 600 mcg/kg/day for 3 days 
versus placebo, squares: 300 mcg/kg/day for 3 days versus placebo, and whiskers: 95%CI’s). 
Figure S1 Flowchart of pharmacokinetic model applied separately to both ivermectin and 
piperaquine. Where ka is the absorption rate in hours. X1, X2, X3, and X4, respectively, represent the 
drug mass (in grams) in the gut (dose compartment), the blood (central compartment), and the two 
extra peripheral compartments (one for ivermectin). ke represents the elimination rate in hours and 
is calculated as clearance (CL/F) divided by the central volume of distribution (V/F). Q1/F, VP1/F, 
Q2/F, and VP2/F represent the exchange rates between the central and the two extra peripheral 
compartments (one for ivermectin) in hours. CapVen ratio represents the parameter that quantifies 
the ratio between capillary and venous concentration. 
Figure S2 Capillary versus venous concentration ratios for ivermectin and piperaquine. Open circles 
represent observed individual ratios for each patient at each time point. (a) Ivermectin capillary-
venous ratio based on simultaneous PK-PD population model, median [IQR]: 1.33 [0.98-1.63]. (b) 
Ivermectin capillary-venous ratio over sampling time (ball-whiskers indicate median±IQR per 
sampling day) (c) Piperaquine capillary-venous ratio based on PK population model, median [IQR]: 
1.54 [1.1-2.8]. 
Figure S3 Ivermectin versus mosquito mortality (%) dose-response curves (LC50 method). Using data 
from all study visits, mosquito mortality (expressed as a percentage) was assessed at the specified 
number of days (7, 10, or 14) post-feeding. In unadjusted models, baseline mortality is disregarded 
by forcing the model to pass through the origin. In adjusted models, baseline mortality is considered, 
where the Lethal Concentration 50% (LC50) is the concentration required to kill 50% of mosquitoes 
that would have otherwise survived the assay without ivermectin exposure. LC50 values are shown in 
Table S3. 
Figure S4 Residual analysis of mosquito mortality rates (i.e. ivermectin’s pharmacodynamic effect) 
over time, as predicted by the simultaneous PK-PD model versus observed data. The lack of a time 
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bias between study visits (Kruskal-Wallis: p<0.05; n=109-141) indicates a consistent concentration-
effect relationship (EC50 and Emax) through-out the study duration. 
Figure S5 Piperaquine versus QTcF dose-response curves. (a) Linear relationship between pooled (all 
arms) observed venous piperaquine concentration (ng/mL) and observed change in QTcF (∆QTcF) 
from baseline in ms. (b) Sigmoidal relationship between pooled observed venous piperaquine 
venous concentrations and observed QTcF. Open circles represent observed data (n=251 
concentrations above LOQ with paired QTcF). The solid line represents the median fit and dashed 
lines represent the 5-95 percentile limits of the fit. (c) Individual predicted QTcF versus observed 
QTcF according to the piperaquine population PK-PD Emax based model. (d) Population predicted 
QTcF versus observed QTcF according to the piperaquine population PK-PD Emax based model. 
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Table 1 Primary and secondary PK parameters for ivermectin and piperaquine. Ivermectin parameters are reported using 
either the sequential PK-PD model (where PK analysis was done on venous and capillary PK data only) or the simultaneous 
PK-PD model (where PK-PD analysis was performed simultaneously on venous and capillary exposure data as well as PD 
outputs defined as corresponding mosquito mortality rates for each venous sample). WT=bodyweight. NA=not available. 
*For ivermectin models, only subjects in the ivermectin arms.
Parameter 
IVERMECTIN 
Sequential 
PK-PD model 
IVERMECTIN 
Simultaneous 
PK-PD model 
PIPERAQUINE 
 Median 
[p5-p95] 
± Inter-individual 
variability (%) 
 Median 
[p5-p95] 
± Inter-individual 
variability (%) 
Median 
[p5-p95] 
± Inter-individual 
variability (%) 
V / F (L) 147.0 [36.2-582.0] 
× (WT/60) 
±103.0 
161.7 [70.9-760.4] 
× (WT/60) 
±112.7 
803.7 [149.1-1999] 
× (WT/60) 
±69.0 
CL / F (L/h) 9.6 [6.5-14.6] 
× (WT/60)0.75
±39.1 
10.9 [6.6-26.1] 
× (WT/60)0.75
±57.4 
97.1 [20.0-177.3] 
× (WT/60)0.75
±49.1 
ka (h-1) 0.22 [0.082-1.79] 
±157.1 
0.474 [0.15-6.93] 
±163.5 
1 (fixed) 
Q1 / F (L/h) 19.0 [7.7-113.1] 
±104.7 
21.1 [9.7 – 116.4] 
±100.5 
1017.0 [197.5-4079] 
±87.5 
VP1 / F (L) 1148.1 [413.1-3845] 
±86.6 
612.4 [253.0-1879] 
±82.1 
3796 [415.1-14918] 
±165.8 
Q2 / F (L/h) NA NA 156.4 [32.6-545.7] 
±82.8 
VP2 / F (L) NA NA 35993 [7586-146968] 
±96.2 
Capillary/venous ratio 1.32 [1.1-1.6] 
±18.7 
1.33 [0.98-1.63] 
±29.1 
1.55 [1.1-2.8] 
±36.1 
Secondary parameters 
Cmax (ng/mL) 
All subjects 
0 mcg/kg/day IVM arm 
300 mcg/kg/day IVM arm 
600 mcg/kg/day IVM arm 
NA 
NA 
64.1 [29.7-129.9] 
105.2 [44.5-482.5] 
NA 
NA 
69.4 [34.1 -196.3] 
118.9 [45.2-455.1] 
252.4 [95.5-1072.5] 
250.1 [99.4-727.7] 
263.6 [84.6-1268.2] 
246.2 [98.8-990.1] 
Tmax (h) – after last dose 
All subjects* 
0 mcg/kg/day IVM arm 
300 mcg/kg/day IVM arm 
600 mcg/kg/day IVM arm 
4.8 [0.58-8.7] 
NA 
5.0 [1.4-8.8] 
3.5 [0.40-7.5] 
2.9 [0.46-7.8] 
NA 
3.9 [0.75-7.6] 
2.3 [0.43-8.2] 
1.4 [1.1-3.6] 
1.4 [1.1-3.5] 
1.4 [1.1-3.0] 
1.5 [1.1-3.8] 
Terminal t1/2 (h)  
All subjects* 
0 mcg/kg/day IVM arm 
300 mcg/kg/day IVM arm 
600 mcg/kg/day IVM arm 
4.9 [1.9 – 12.9] 
NA 
5.1 [2.2-12.6] 
4.7 [1.7-12.5] 
3.1 [0.93-11.4] 
NA 
2.9 [1.1-7.8] 
3.2 [0.90-8.5] 
17.7 [2.6-81.8] 
18.2 [5.7-89.8] 
17.2 [2.8-94.6] 
17.9 [1.5-42.3] 
AUC0-28d (h • mcg/mL) 
All subjects 
0 mcg/kg/day IVM arm 
300 mcg/kg/day IVM arm 
600 mcg/kg/day IVM arm 
NA 
NA 
5.5 [2.5-8.3] 
10.0 [1.7-22.3] 
NA 
NA 
5.0 [1.6-8.3] 
9.3 [2.1-25.0] 
21.4 [6.3-47.9] 
21.3 [10.4-44.9] 
23.7 [6.9-49.7] 
21.2 [6.5-46.5] 
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Table 2 Pharmacodynamic parameters of ivermectin as determined using (1) observed venous concentrations only, (2) 
predicted venous concentrations from the sequential PK model, or (3) using a simultaneous PK-PD model which 
incorporates PK and PD data in the analysis process. Emin was fixed to 3.7 for (1) and (2) based on baseline and control 
mortality. Exx is the percentile of effect between Emin and Emin+Emax. ECxx is the concentration at which Exx is achieved. Txx is 
the time post-treatment at which ECxx and Exx are achieved. 
 
Models based on:  
Obs. Venous Conc.  
versus Mosq. Effect  
(Pooled Data) 
Sequential 
Pred. Venous Conc.  
versus Mosq. Effect 
(Pooled Data) 
Simultaneous 
PK-PD model 
(Population 
Modelling) 
Parameter Median [p5-p95] Median [p5-p95] Median [p5-p95] 
Mosquitocidal effect    
   Emin (deaths/100 days) 3.7 (fixed) 3.7 (fixed) 3.9 [2.9-5.8] 
   E1 (deaths/100 days) 4.18 [4.16-4.21] 4.22 [4.19-4.25] 4.40 [4.23-4.53] 
   E5 (deaths/100 days) 6.14 [6.02-6.25] 6.31 [6.18-6.47] 6.38 [5.54-7.08] 
   E50 (deaths/100 days) 28.1 [23.2-29.3] 29.9 [28.5-31.4] 28.7 [20.1-35.5] 
   E95 (deaths/100 days) 50.1 [47.7-52.3] 53.4 [50.8-56.2] 50.7 [34.9-64.1] 
   Emax + Emin (deaths/100 days) 52.5 [50.0-54.9] 56.0 [53.3-59.0] 53.4 [36.7-67.5] 
Effective Concentration    
   EC1 (ng/mL) 0.11 [0.095-0.14] 0.17 [0.14-0.19] 0.16 [0.053-0.37] 
   EC5 (ng/mL) 0.90 [0.51-1.14] 0.84 [0.74-1.0] 0.83 [0.28-1.9] 
   EC50 (ng/mL) 11.3 [9.5-13.6] 16.5 [14.1-19.2] 15.9 [5.3-36.4]  
   EC95 (ng/mL) 214.3 [178.2-259.0]  314 [269.3-374.3] 302.1 [100.7-691.6] 
Time above EC (IVM-3x300)    
   T1 (days) 33.3 [19.0-130.5] 30.1 [17.9- 115.4] 24.4 [10.5-63.0] 
   T5 (days) 22.6 [13.4-56.4] 20.3 [12.2-50.9] 17.0 [8.0-42.6] 
   T50 (days) 5.6 [2.4-12.7] 3.9 [2.2-8.9] 4.1 [NA-8.1] 
   T95 (days) NA NA NA 
Time above EC (IVM-3x600)    
   T1 (days) 38.0 [21.6-150.1] 34.5 [20.0-142.2] 28.1 [11.5-72.8] 
   T5 (days) 27.4 [15.4-66.0] 24.8 [14.3-60.4] 20.1 [9.3-52.9] 
   T50 (days) 9.0 [3.0-20.7] 7.1 [2.6-16.4] 6.8 [2.5-14.7] 
   T95 (days) NA NA NA 
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